KCT0000445
Recruiting
未知
Safety and efficacy of allogeneic umbilical cord blood therapy for children with global developmental delay
Bundang CHA General Hospital0 sites10 target enrollmentTBD
ConditionsDiseases of the nervous system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the nervous system
- Sponsor
- Bundang CHA General Hospital
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Global developmental delay
- •2\. Written consent of a legal representative
- •3\. Willing to comply with all study procedure and participate in the study for 12 months
- •4\. Eligible depending on the principle investigator
Exclusion Criteria
- •1\. Aspiration pneumonia, impaired renal function, uncontrolled epilepsy at enrollment
- •2\. Poor cooperation with study procedure
- •3\. Persistent epilepsy despite of three kinds of antiepileptic drugs
- •4\. Not eligible according to the priciple investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Allogeneic UCB Therapy With EPO in Children With CPDiseases of the nervous systemKCT0000950Bundang CHA General Hospital120
Completed
Not Applicable
Allogeneic UCB Therapy With EPO in Children With CPCerebral PalsyNCT01991145MinYoung Kim, MD, PhD92
Completed
Phase 1
Allogeneic Umbilical Cord Blood Therapy for StrokeStrokeNCT01884155MinYoung Kim, M.D.5
Completed
Phase 2
Effects of umbilical cord derived stem cells injection in the treatment of children with cerebral palsyIRCT201706176907N13Tehran University of Medical Sciences108
Completed
Phase 1
Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral PalsyCerebral PalsyNCT02599207Joanne Kurtzberg, MD15